SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-055300
Filing Date
2018-10-17
Accepted
2018-10-17 16:13:53
Documents
2
Period of Report
2018-10-15

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1629
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 3513
  Complete submission text file 0001209191-18-055300.txt   6597
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Issuer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016
Business Address
Neumann Mark (Reporting) CIK: 0001756211 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36274 | Film No.: 181126531